News Discovery of KT-474, a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases 9/26/23 Read more Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders 7/24/23 Read more Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors 6/14/23 Read more Pulse Dosing of Potent and Selective Heterobifunctional MDM2 Degrader KT-253 Drives Tumor Regression and Demonstrates Differentiated Pharmacology Compared to p53/MDM2 Small Molecule Inhibitors 6/9/23 Read more Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader 12/12/22 Read more Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of IRAKIMiD sand BCL2 Inhibition 12/12/22 Read more Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the treatment of Acute Myeloid Leukemia 12/11/22 Read more Proteomics enabling TPD Drug Discovery 12/7/22 Read more Discovery of a First-In-Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP-53 Wt AML & Solid Tumors 10/27/22 Read more Expression & Characterization of Novel Tissue Selective E3 Ligases 10/25/22 Read more
